Speaking To Mobiquitiy About The Whats And Hows For Digital Platforms

Health care is undergoing a transformation as more and more treatments become partially-digitized. However, building the platforms required is difficult, meaning many companies call for third-party help. Medtech Insight spoke to one player in this space, Mobiquity, to learn more about the process.

• Source: Shutterstock

Mobiquity, part of Hexaware, has built up extensive experience navigating the challenges of patient-facing digital applications for life sciences clients like Johnson & Johnson, Phillips, Roche, Merck and Alcon.

Speaking to Medtech Insight, Mobiquity’s strategy director, healthcare and life sciences, Teun Schutte, broke down the differences between the health care sector and the other markets the company serves

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Medtech Insight

Does Makary’s Reorg Choice Mark FDA Turning Point?

 

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

New Treatment For Chronic Facial Pain Could Launch By Fall 2025

 
• By 

NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.